CAMP and lung disorder: Clinical observations have indicated the elevation of LL‐37 expression in lung disease exacerbation (Schaller‐Bals et al, 2002; Pouwels et al, 2015), suggesting that pulmonary infection and inflammation could activate the LL‐37‐based protective mechanism.